Article

Insights into the Multi-Azole Resistance Profile in Candida haemulonii Species Complex

Laura Nunes Silva 1, Lívia de Souza Ramos 1, Simone Santiago Carvalho Oliveira 1, Lucas Barros Magalhães 1, Eamim Daidré Squizani 2, Lívia Kmetzsch 2, Marilene Henning Vainstein 2, Marta Helena Branquinha 1 and André Luis Souza dos Santos 1,3,*

1 Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes (LEAMER), Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes (IMPG), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-901, Brazil; lauransilva@gmail.com (L.N.S.); liviamagos2@yahoo.com.br (L.d.S.R.); simonesantiagorj@yahoo.com.br (S.S.C.O.); lbarrosmagalhaes@gmail.com (L.B.M.); mbranquinha@micro.ufrj.br (M.H.B.)
2 Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul 91540-000, Brazil; eamimsquizani@gmail.com (E.D.S.); liviak@cbiot.ufrgs.br (L.K.); mhv@cbiot.ufrgs.br (M.H.V.)
3 Programa de Pós-Graduação em Bioquímica (PPGBq), Instituto de Química (IQ), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-909, Brazil
* Correspondence: andre@micro.ufrj.br; Tel.: +55-21-3938-0366

Received: 15 September 2020; Accepted: 8 October 2020; Published: 11 October 2020

Abstract: The Candida haemulonii complex (C. duobushaemulonii, C. haemulonii, and C. haemulonii var. vulnera) is composed of emerging, opportunistic human fungal pathogens able to cause invasive infections with high rates of clinical treatment failure. This fungal complex typically demonstrates resistance to first-line antifungals, including fluconazole. In the present work, we have investigated the azole resistance mechanisms expressed in Brazilian clinical isolates forming the C. haemulonii complex. Initially, 12 isolates were subjected to an antifungal susceptibility test, and azole cross-resistance was detected in almost all isolates (91.7%). In order to understand the azole resistance mechanistic basis, the efflux pump activity was assessed by rhodamine-6G. The C. haemulonii complex exhibited a significantly higher rhodamine-6G efflux than the other non-albicans Candida species tested (C. tropicalis, C. krusei, and C. lusitaneae). Notably, the efflux pump inhibitors (Phe-Arg and FK506) reversed the fluconazole and voriconazole resistance phenotypes in the C. haemulonii complex. Expression analysis indicated that the efflux pump (ChCDR1, ChCDR2, and ChMDR1) and ERG11 genes were not modulated by either fluconazole or voriconazole treatments. Further, ERG11 gene sequencing revealed several mutations, some of which culminated in amino acid polymorphisms, as previously reported in azole-resistant Candida spp. Collectively, these data point out the relevance of drug efflux pumps in mediating azole resistance in the C. haemulonii complex, and mutations in ERG11p may contribute to this resistance profile.

Keywords: azole resistance; efflux pumps; fluconazole; lanosterol 14α-demethylase; non-albicans Candida species; voriconazole

1. Introduction

The recently described Candida haemulonii clade has caused deep concerns in hospital environments worldwide, since its members are able to cause life-threatening infections presenting high rates of clinical treatment failures [1]. The C. haemulonii clade is composed of emerging, opportunistic,
and multidrug-resistant species formed by *C. auris*, *C. duobushaemulonii*, *C. haemulonii* sensu stricto, *C. haemulonii* var. *vulnera*, *C. pseudohaemulonii*, and *C. vulturna* [1,2].

*Candida duobushaemulonii*, *C. haemulonii*, and *C. haemulonii* var. *vulnera*, which form the *C. haemulonii* complex, have been identified in different geographic regions in the globe, prominently in Latin American (e.g., Brazil) and Asian (e.g., India and China) countries. However, not surprisingly Coles et al. [3] highlighted the possible emergence of these fungal pathogens also in the United States of America. This fungal complex is often associated with bloodstream infections, onychomycosis, vaginal infections, catheter-related fungemia, and outbreaks in neonatal intensive care units [3–9]. In Brazil, most of the studies reported candidemia by the *C. haemulonii* species complex, associated with high antifungal resistance profiles [10–13]. Since phenotypic identification methods cannot accurately distinguish among these species, the prevalence of *C. haemulonii* species complex in hospital settings may be underestimated. In this sense, a 10.5-year analysis conducted between 1997 and 2007 by the ARTEMIS DISK Global Antifungal Surveillance Study demonstrated that infections caused by *C. haemulonii* were rare (less than 0.01%) at that moment [14]. In 2012, *C. haemulonii* was identified as the third cause of candidemia in a hospital in New Delhi, India, corresponding to 15.5% of the cases [15]. Lately, Xiao et al. [16] reported surveillance results on candidemia from 77 Chinese hospitals, where the prevalence of *C. haemulonii* rose from 0.6% to 0.9% in the 3-year investigation period (2015–2017). Additionally, a recent study from Brazil demonstrated an increased prevalence of the *C. haemulonii* species complex from 0.9% in the first period of the analysis (2008-2013) to 1.7% in the second period (2014-2019) [17].

The *C. haemulonii* species complex typically demonstrates resistance to amphotericin B (AMB) and fluconazole as well as a variable susceptibility to the novel azoles (e.g., voriconazole, posaconazole, and isavuconazole) and echinocandins (e.g., caspofungin, micafungin, and anidulafungin) [18–20]. Recently, our research group described primary evidence suggesting that resistance to AMB is due to multifactorial events displayed by the species belonging to the *C. haemulonii* complex, including reduced ergosterol content located in the plasma membrane, mitochondrial dysfunction, resistance to oxidative stressors, and the upregulation of the antioxidant machinery [21].

Fluconazole is the most widely used antifungal agent in hospital settings for both treatment and prophylaxis approaches. However, fluconazole resistance is particularly prominent in the *C. haemulonii* species complex, with most of the clinical isolates presenting a typical resistant profile to this triazole antifungal [18,20]. The main mechanism of action of azole antifungals involves the blockage of the ergosterol synthesis pathway in fungal cells, specifically by inhibiting the lanosterol 14α-demethylase, an enzyme encoded by the *ERG11* gene. The lanosterol 14α-demethylase (ERG11p) inhibition leads to the accumulation of aberrant sterol intermediates at the plasma membrane, inducing severe toxic effects that culminate in the interruption of fungal growth. Mutations in the *ERG11* gene are one of the most important mechanisms described forazole resistance in *Candida* spp. [22]. Nevertheless, it is well known that a fungus can orchestrate more than one mechanism of action in order to become resistant to azoles, including the upregulation of the ERG11 gene and the overexpression of efflux pumps mainly encoded by multidrug-resistance (MDR) and candida drug resistance (CDR) genes [22]. Although recent studies have suggested that mutations in the *ERG11* gene lead to the production of altered ERG11p in *C. auris* [23,24], an analysis of the genomic and transcriptomic data of *C. haemulonii* clade also impute the upregulation of the CDR1 gene as an important mechanism explainingazole resistance [23–25].

Thus far, no *C. auris*, *C. pseudohaemulonii*, and *C. vulturna* isolates has been described in Brazil. Since many reports have suggested intrinsic resistance to fluconazole and in vitro multidrug-resistance to azoles, we have examined the above-mentioned resistance mechanisms among 12 Brazilian clinical isolates of the *C. haemulonii* species complex. To accomplish this, we have evaluated the (i) in vitro susceptibility to different azoles; (ii) the efflux pump activity; (iii) the expression level of *ERG11*, MDR-like, and CDR-like genes; and (iv) mutations in the *ERG11* gene, which support the alterations in ERG11p that is the azoles’ target.
2. Materials and Methods

2.1. Fungal Isolates and Culture Conditions

Twelve clinical isolates of the *C. haemulonii* complex were used in this study: *C. haemulonii* (LIPCh2, LIPCh3, LIPCh4, LIPCh7, and LIPCh12), *C. duobushaemulonii* (LIPCh1, LIPCh6, LIPCh8, and LIPCh10), and *C. haemulonii* var. *vulnera* (LIPCh5, LIPCh9, and LIPCh11), identified by ITS gene sequencing, as previously described by our research group [10]. For a comparative purpose, three reference non-*albicans* Candida species were also used: *C. tropicalis* (ATCC 750), *C. krusei* (ATCC 6258), and *C. lusitaniae* (ATCC 200950). In all experiments, Sabouraud-dextrose medium was used to culture the fungal isolates at 37 °C for 48 h under constant agitation (200 rpm). Yeast cells were counted using a Neubauer chamber.

2.2. Antifungal Susceptibility Assay

Antifungal susceptibility testing was performed according to the standardized broth microdilution technique described by the Clinical and Laboratory Standards Institute (CLSI) in document M27-A3 and interpreted according to document M27-A3 [26]. The tested antifungal drugs include fluconazole (FLC), itraconazole (ITC), ketoconazole (KTC), posaconazole (PSC), and voriconazole (VRC) (Sigma-Aldrich, USA). The minimum inhibitory concentration (MIC), modal MIC, geometric mean (GM)-MIC, MIC₉₀, median, and antifungal concentration range were calculated using Prism version 8 (GraphPad Software, USA). Until now, no species-specific clinical breakpoints are established for rare species regarding azole susceptibility both in CLSI and EUCAST. In this sense, the manuscripts focused on this fungal complex usually base their results on the CLSI breakpoints established for the *Candida* genus (CLSI document M27-A3) in order to have a minimum (even not precisely) parameter to interpret these data. The clinical breakpoints defined for *Candida* spp. were used for the interpretation of the MIC data as follows: susceptible (S) ≤8 mg/L, susceptible-dose dependent (S-DD) 16–32 mg/L, resistant (R) ≥64 mg/L for FLC; S ≤0.125 mg/L, S-DD 0.25–0.5 mg/L, R ≥1 mg/L for ITC; S ≤1 mg/L, S-DD 2 mg/L, R ≥4 mg/L for VRC. For PSC, the susceptibility breakpoint was considered 0.06 mg/L, determined by EUCAST for *Candida* spp. No interpretive criteria for KTC are available in either the CLSI or EUCAST documents.

2.3. Efflux Pump Activity

To assess the ABC-type drug transporter activity of fungal cells, we evaluated the glucose-induced efflux of rhodamine 6G (R6G) (Sigma-Aldrich, USA) assay, as previously described [6,27]. Yeasts (10⁷ cells/mL) were incubated with R6G (10 µM) to enable uptake under carbon source-depleted conditions for 60 min. Cells were washed in phosphate-buffered saline (PBS), and tubes with glucose-free PBS (control) and PBS supplemented with 100 mM of glucose were prepared to start R6G efflux. Finally, after 1 and 3 h of incubation with glucose at 37 °C, the cells were quantified in a flow cytometer (FACSCalibur, BD Bioscience, USA) and analyzed at 527 nm. Representative data from the 10,000 events analysis were shown and the results were expressed as the percentage of fluorescent cells (%FC). Fungal cells not stained with R6G were used as a negative control. In parallel, a different group was also pretreated for 1.5 h with FLC (64 mg/L) and VRC (16 mg/L) before the addition of R6G and glucose.

2.4. Chemosensitization Assay Combining Efflux Pump Inhibitors and Azoles

The efflux pump inhibitors (EPIs), Phe-L-Arg-β-naphthylamine dihydrochloride (Phe-Arg) and tacrolimus (FK506) (Sigma-Aldrich, USA), were used in combination with FLC or VRC in order to determine if the antifungal activity could be enhanced [28]. MICs were developed in the presence of azole (64 to 0.125 mg/L) with and without the presence of each EPI at a concentration of 64 mg/L. All the systems were incubated for 48 h at 37 °C and the results were expressed as the lowest azole concentration that resulted in the total inhibition of visible fungal growth.
2.5. RNA Extraction

After initial culture conditions (item 2.1), C. *haemulonii* isolate LIPCh4 (a panazole *C. haemulonii sensu strictu* isolate) was diluted to an initial inoculum of $10^7$ cells/mL in fresh Sabouraud (20 mL) and then exposed to FLC at 64 mg/L or VRC at 16 mg/L for 1.5 h with shaking. Following drug exposure, the fungal cells were harvested for RNA isolation as previously described [29]. Complementary DNA (cDNA) was synthesized with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems™, Thermo Scientific, USA).

2.6. Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-qPCR)

RT-qPCR was undertaken to estimate the expression of the ChCDR1, ChCDR2, ChMDR1, and ChERG11 ortholog genes by *C. haemulonii* complex strains during FLC or VRC exposure (after 1.5 h of exposure). cDNA was analyzed by RT-qPCR with the StepOne™ Real-Time PCR System (Applied Biosystems™, Thermo Scientific, USA) and specific primers (Table 1). Universal SYBR green Supermix was used for PCRs according to the manufacturer’s recommendations. The $2^{-\Delta\Delta CT}$ method was used for the relative quantification of gene expression [30], and the data were normalized to the ACT1 (actin) gene expression.

| Oligonucleotides a | Sequences (5’ to 3’) | Purpose—Accession Number b |
|--------------------|----------------------|-----------------------------|
| ERG11_CH_F1        | CATTTTCAGGCCCTTGCCCAC | ERG11 sequencing *Candida haemulonii*-XM_025486744.1 |
| ERG11_CH_R1        | TCTGGGCACGATCTCTCAGA  |                             |
| ERG11_CH_F2        | ACTGCTTTAACCAAGAGGAGC |                             |
| ERG11_CH_R2        | AAGCTACCACCTTTGGAGAGC |                             |
| ERG11_CH_F3        | TTIGGCTCCCAAAGGTTGC   |                             |
| ERG11_CH_R3        | CGCATGTCTCCCTCTTCTCC  |                             |
| ERG11_CD_F1        | CGGTATGCAGCCATACGAGT  | ERG11 sequencing *Candida duobushaemulonii*-XM_025482007.1 |
| ERG11_CD_R1        | CGCCAATCAACAAGTGGCA   |                             |
| ERG11_CD_F2        | TCCAGAGATACGTGCCCAGA  |                             |
| ERG11_CD_R2        | ACACAGAGACATCCTGCGT   |                             |
| ERG11_CD_F3        | CTGCCTGGTTCTTTGTCAC   |                             |
| ERG11_CD_R3        | AGTCAACAGGTTGGAACGCC  |                             |
| ACT1_CH_F1         | ACTGCTTTTGGCTCCATGCT  | ACT1 real-time PCR—XM_025485061.1 |
| ACT1_CH_R1         | AGACTCGTCGTACTCCCTCT  |                             |
| ERG11_CH_F1        | CTGGATCCATGGTTTGCTTG  | ERG11 real-time PCR—XM_025486744.1 |
| ERG11_CH_R1        | GTCAATAGCGAGTAAAGGCC  |                             |
| CDR1_CH_F1         | ACTTGTCATGCAAGAACCAC  | CDR1 real-time PCR—XM_025483931.1 |
| CDR1_CH_R1         | GGTAGCGCCTCTCTGCTACT  |                             |
| CDR2_CH_F1         | ATCGAGACGGGTAGAGTG    | CDR2 real-time PCR—XM_025488660.1 |
| CDR2_CH_R1         | CACCAGAGCAACCTAACAT   |                             |
| MDR1_CH_F1         | GTCCCTCGTGGCAAAACC    | MDR1 real-time PCR—XM_025484012.1 |
| MDR1_CH_R1         | AGGGCTAGCAGGAGCCTTG   |                             |

* The letters F and R in the primer names describe the 5’-to-3’ orientations of the primers as follows: F, forward (sense); R, reverse (antisense). b NCBI reference sequence.

2.7. Amplification and Sequencing of the ERG11 Gene

The ERG11 gene encoding lanosterol 14α-demethylase was amplified and sequenced with specific primers (Table S1). The BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA) was used for sequencing the reaction, precipitated with ethanol/EDTA/sodium acetate according to the protocol suggested by the manufacturer and sequenced on the ABI3730xl DNA Analyzer platform (Applied Biosystems, USA). DNA sequences and the corresponding amino acid sequences were analyzed with the SeqMan II and Bioedit software packages (Lasergene; DNASTar, USA). Consensus sequences were aligned with different reference ERG11 sequences from *Candida* spp. For the mutation
analysis, the C. albicans strain SC5314 ERG11 gene assembly sequence from Candida Genome Database (http://www.candidagenome.org/) was used [31–33].

2.8. Sequences Accessions

The ERG11 gene sequences obtained from clinical isolates belonging to the C. haemulonii species complex studied herein were deposited in GenBank with the following accession numbers: MT860384 to MT860395.

2.9. Statistics

All the experiments were performed in triplicate, in three independent experimental sets. The results were analyzed statistically by the Analysis of Variance One-Way ANOVA (comparisons between three or more groups). All the analyses were performed using the program GraphPad Prism8. In all analyses, p values of 0.05 or less were considered statistically significant.

3. Results

3.1. Azoles’ Susceptibility Profiles

The MIC values determined for 12 clinical isolates forming the C. haemulonii species complex (C. haemulonii, n = 5 isolates; C. duobushaemulonii, n = 4; and C. haemulonii var. vulnera, n = 3) against five different azoles (FLC, ITC, KTC, PSC, and VRC) were summarized in Table 2 and Table S1. Among the tested azoles, PSC (GM-MIC = 0.62 mg/L) and KTC (GM-MIC = 1.49 mg/L) exhibited potent antifungal activity against all the isolates studied. Notably, all the fungal isolates had MICs of ≥64 mg/L for FLC. For ITC, a modal MIC of ≥16 mg/L was noted, suggesting that all the isolates were resistant to this antifungal. Despite some isolates remaining susceptible to VRC, the MIC distribution exhibited a peak at 16 mg/L, with 66% (n = 8) of isolates being resistant to this azole. Nine isolates (75%) were resistant to at least two different azoles. Six isolates (50%) were considered pan-azole resistant, of which four belong to the species C. haemulonii senso strictu, one belongs to C. duobushaemulonii, and one belongs to C. haemulonii var. vulnera.
Table 2. MIC distribution of the *C. haemulonii* species complex (\(n = 12\) isolates) against five azole agents tested using the CLSI standard method.

| Azoles | 0.016 | 0.032 | 0.064 | 0.125 | 0.25 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | Range | GM-MIC | MIC\(_{50}\) | MIC\(_{90}\) |
|--------|-------|-------|-------|-------|------|---|---|---|---|----|----|----|-------|---------|---------|---------|
| FLC    |       |       |       |       |      |   |   |   |   |    |    |    | -     | 64      | 64      | 64      |
| ITC    | 1     | 2     | 1     | 3     | 5    |   |   |   |   |    |    |    | 0.25-16| 4.23    | 8       | 16      |
| VRC    | 1     | 2     | 1     | 8     |      |   |   |   |   |    |    |    | 0.25-16| 4.75    | 16      | 16      |
| PSC    | \(\underline{\text{3}}\) | 1     | 1     | 2     | 1    | 2 |   |   |   |    |    |    | 0.03-16| 0.62    | 0.5     | 16      |
| KTC    | 1     | 2     | 2     | 4     | 2    | 1 |   |   |   |    |    |    | 0.125-16| 1.49    | 2       | 12.4    |

FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; PSC, posaconazole; KTC, ketoconazole. MIC, minimum inhibitory concentration. \(^{a}\) GM-MIC, geometric mean MIC. \(^{b}\) MIC\(_{50}\), MIC at which 50% of the test isolates were inhibited. \(^{c}\) MIC\(_{90}\), MIC at which 90% of the test isolates were inhibited. Modal MICs are indicated with underlined numbers.
3.2. Efflux Pumps Play a Primary Role in Azole Resistance in C. haemulonii Complex

In this set of experiments, we firstly assessed the efflux pump activity by the extrusion of RG6. When compared with other non-albicans Candida species (C. tropicalis, C. lusitaniae, and C. krusei), C. haemulonii exhibited a significantly higher R6G efflux after 1 h (Figure 1) (Table S2). Analyzing the glucose-induced R6G efflux in the three different species forming the C. haemulonii complex, we could not observe statistical differences between them over 3 h (Figure 2). Interestingly, the efflux pump activities have been shown to be constitutively expressed within fungal cells, since the treatment with either FLC or VRC did not modulate the glucose-induced efflux of RG6 (Figure 2).

**Figure 1.** Flow cytometry analysis of the glucose-induced rhodamine 6G (R6G) efflux. Uptake of fluorochrome was quantified by incubating yeast cells in PBS for 60 min with 10 µM of R6G (red curve). Next, efflux was evaluated by quantifying the residual fluorescence of the cells after the removal of the free dye and with an additional incubation in phosphate-buffered saline (PBS) supplemented with 100 mM of glucose (orange curve). Fungal species: (A) C. tropicalis (ATCC 750), (B) C. krusei (ATCC 6258), (C) C. lusitaniae (ATCC 200950), and (D) C. haemulonii (LIPCh4). Each experiment was performed at least for three independent times with similar results.
Since it seems that efflux pump activities are constitutively present in the *C. haemulonii* complex, as the FLC and VRC treatment did not modify the R6G extrusion process, we next examined the expression of the genes coding for known azole transporters. In an effort to identify the efflux pump-encoding genes which could participate in the clinical azole resistance in the *C. haemulonii* complex, *CDR1*-like, *CDR2*-like, and *MDR1*-like genes were identified by the BLAST approach using the recently updated genome of *C. haemulonii* (strain B11899), which presented the highest degree of homology genes to *C. albicans*. The *C. haemulonii* genes with the highest degree of homology to the *C. albicans CDR1* and *CDR2* genes were XM_025483931.1 and XM_025488660.1, here referred to as *ChCDR1* and *ChCDR2* (Table S2), respectively; the *C. haemulonii* gene with a greater degree of homology with the *C. albicans MDR1* gene was XM_025488295.1, here referred to as *ChMDR1* (Table S3). Our data showed that the *ChCDR1, ChCDR2, and ChMDR1* genes were not modulated by the azole treatment (Figure 3). A similar result was observed considering the expression of the *ERG11* gene (Figure 3).

**Figure 2.** Flow cytometric efflux of rhodamine 6G (R6G) over time among clinical isolates belonging to the *C. haemulonii* species complex. Data were expressed as the percentage of fluorescent cells (%FC) after the addition of 100 mM of glucose. Some systems were also pretreated for 1.5 h with fluconazole (FLC at 64 mg/L) and voriconazole (VRC at 16 mg/L) prior to the R6G and glucose supplementation. Fungal species: *C. haemulonii LIPCh4* (Ch4), *C. duobushaemulonii LIPCh8* (Ch8), and *C. haemulonii var. vulnera LIPCh9* (Ch9). The results were expressed as the mean ± standard deviation of three independent experiments, and the symbol (**) represents p values ≤ 0.01 when compared to control (one-way ANOVA, Bonferroni post hoc test).

**Figure 3.** Expression of the *CDR1, CDR2, MDR1, and ERG11* genes in *C. haemulonii*. The expression of target genes was determined by RT-qPCR in the clinical isolate of *C. haemulonii LIPCh4*. A pre-treatment was conducted 1.5 h earlier with fluconazole (FLC at 64 mg/L) and voriconazole (VRC at 16 mg/L) before the RNA extraction. Actin gene (*ACT1*) was used as a housekeeping gene. The results were expressed as the mean ± standard deviation of three independent experiments.
We then assessed the contribution of these transporters to azole sensitivity by blocking them with classical EPIs (Table 3). When the isolates were grown in the presence of a combination of an azole (FLC or VRC) plus an EPI (Phe-Arg or FK506), we can observe that the MIC decreased in a 4- to more than 64-fold range. Remarkably, all the tested fungal isolates reversed their resistance phenotypes with the addition of EPIs.

**Table 3.** Effect of the inhibition of efflux pumps (EPIs) on the azole susceptibility in clinical isolates of the *C. haemulonii* species complex.

| Isolates  | Azoles | MIC | MIC + Phe-Arg | Variation | MIC + FK506 | Variation |
|-----------|--------|-----|---------------|-----------|-------------|-----------|
| LIPCh4    | FLC    | >64 | 2             | ≥32x      | 8           | ≥8x       |
|           | VRC    | >16 | 0.25          | ≥64x      | 1           | ≥16x      |
| LIPCh5    | FLC    | 64  | 2             | ≥32x      | 4           | ≥16x      |
|           | VRC    | 0.5 | 0.0625        | 8x        | 0.125       | 4x        |
| LIPCh6    | FLC    | 64  | 2             | 32x       | 4           | 16x       |
|           | VRC    | 1   | 0.0625        | 8x        | 0.25        | 4x        |
| LIPCh7    | FLC    | >64 | 2             | ≥32x      | 8           | ≥8x       |
|           | VRC    | 16  | 0.25          | 64x       | 1           | 16x       |
| LIPCh8    | FLC    | >64 | 4             | ≥16x      | 8           | 4x        |
|           | VRC    | >16 | 0.5           | ≥32x      | 2           | 8x        |
| LIPCh9    | FLC    | 64  | 4             | 16x       | 8           | 8x        |
|           | VRC    | 16  | 0.125         | 64x       | 0.5         | 32x       |

MIC, minimum inhibitory concentration; FLC, fluconazole; VRC, voriconazole. Phe-Arg and FK506, efflux pump inhibitors. Yeast species: *C. haemulonii* LIPCh4, *C. haemulonii* var. vulnera LIPCh5, *C. duobushaemulonii* LIPCh6, *C. haemulonii* LIPCh7, *C. duobushaemulonii* LIPCh8, and *C. haemulonii* var. vulnera LIPCh9.

3.3. *ERG11* Mutations and Gene Expression Analysis

A phylogenetic tree of *ERG11* genes and their putative orthologs in *Candida* spp. was built by the MEGAX program using the “Maximum likelihood” method, with the intent to identify their phylogenetic relationships (Figure 4). The tree based on a concatenated alignment of *ERG11* genes places *C. auris*, *C. haemulonii*, *C. duobushaemulonii*, and *C. pseudohaemulonii* as a single clade, confirming the close relationship among these fungal species. Our phylogenetic analysis strongly supported that *C. duobushaemulonii* and *C. pseudohaemulonii* were more closely related and form a sister group of *C. haemulonii*, which appeared as the most branched species [23].
Figure 4. Phylogenetic tree of the ERG11 gene from different Candida spp. The alignment was generated by the CLUSTAL W program and the phylogram was constructed using the “Maximum likelihood” method using the MEGAX software [34]. ERG11 and its orthologous amino acid sequences (followed by NCBI access numbers in parentheses): Saccharomyces cerevisiae S288C lanosterol 14α-demethylase (NM_001179137.1), Candida glabrata ATCC 90030 lanosterol 14α-demethylase (KR998002.1), Candida parapsilosis ATCC 22019 lanosterol 14α-demethylase (GQ302972.1), Candida albicans SC5314 lanosterol 14α-demethylase (XM_711668.2), Candida tropicalis ATCC 750 lanosterol 14α-demethylase (KR998015.1), Candida lusitaniae CBS 6936 lanosterol 14α-demethylase (EU919443.1), Candida auris B11221 lanosterol 14α-demethylase (XM_029033208.1), Candida duobushaemulonii B09383 hypothetical protein (XM_025482007.1), Candida pseudohaemulonii B12108 hypothetical protein (XM_024860251.1), and Candida haemulonii 14α-demethylase (XM_025486744.1). The lengths of the branches indicate the average number of changes per site.

By comparing the amino acid sequences of ERG11p, 12 amino acid substitutions were identified in our isolates, all of them have been previously listed in the hot spot (HS) regions I, II, and III of ERG11p of C. albicans and C. auris (Figure 5) [23,35,36]. Of the 12 found substitutions in ERG11p, modifications at positions K119S were only present in C. haemulonii sensu stricto and C. haemulonii var. vulnera, whereas changes at positions R267T and A432S were only detected in C. duobushaemulonii isolates.
who observed that the presence or absence of FLC treatment repeatedly demonstrated the upregulation of the multidrug transporter gene CDR1 in C. haemulonii strains. The majority of the studies has shown that isolates comprising the CDR1 phenotype in the species complex demonstrated high MIC values for AMB, and also frequently to azoles, all directly orchestrated by fungal cells, the upregulation of the efflux pumps ruling the azole resistance [11,12]. Notably, we remain at the very beginning in understanding the biology of these “rare” resistance to this “novel” antifungal class in clinical isolates belonging to the C. haemulonii species complex. Drug resistance has become a major public health issue in terms of managing mainly invasive infections, particularly those resulting from pathogenic fungi that present scarce available effective drugs for treatment. Despite still being considered rare, infections by the C. haemulonii species complex have been highlighted by the high capability of developing multidrug-resistance against all clinically available antifungal classes, representing a challenge to the treatment of patients affected by these fungi. The majority of the studies has shown that isolates comprising the C. haemulonii complex demonstrated high MIC values for AMB and also frequently to azoles, all directly associated with clinical treatment failure [18,20]. In general, susceptibility to echinocandins, such as caspofungin and micafungin, in both vitro and in vivo approaches have been observed [6,37,38]. However, there are already reports of resistance to this “novel” antifungal class in clinical isolates belonging to the C. haemulonii species complex [11,12]. Notably, we remain at the very beginning in understanding the biology of these “rare” fungal opportunistic human pathogens.

Among the diversity of molecular mechanisms related to the antifungal resistance machinery orchestrated by fungal cells, the upregulation of the efflux pumps MDRI and/or CDR1/CDR2 contributes to azole resistance in most clinical isolates of Candida spp. [39]. Our results align with Zhang et al. [24], who observed that the presence or absence of FLC treatment repeatedly demonstrated the upregulation of the multidrug transporter gene CDR1. Additionally, in that study, treatment of the azole-resistant C. haemulonii strains with EPIs partially restored their susceptibility to FLC, confirming the significant contribution of Cdr1p to azole resistance [24]. It is well known that EPIs, such as Phe-Arg and FK506, play a vital role in azole resistance reversal against C. albicans [40], C. glabrata [41], C. tropicalis [42], and C. auris [28]. Consistent with these findings, in the present study, the combination of Phe-Arg or FK506 with FLC or VRC showed synergism against all the resistant isolates forming the C. haemulonii complex. Hence, here we have provided important evidence of efflux pumps ruling the azole resistance phenotype in the C. haemulonii species complex.
For many years, the imidazole KTC was the only available oral agent for the treatment of systemic fungal infections. Nevertheless, the side effects associated with KTC therapy as well as the relatively poor response rates, led to the search for a novel chemical group of azole derivatives, namely the triazoles [43]. Overall, the triazoles demonstrate a broader spectrum of antifungal activity and reduced toxicity when compared with the imidazole derivatives [44]. PSC is a second-generation triazole agent that has been developed mainly to combat the appearance of azoles resistance in yeasts, in particular to FLC. Several in vitro and in vivo studies confirmed that PSC has a broad spectrum of activity against the majority of yeasts, filamentous fungi and azole-resistant Candida. Thus, PSC has a superior activity profile when compared with FLC and ITC [44]. For instance, one way of developing azole resistance is by acquiring mutations on the ERG11 gene. Depending on the position and the nature of the alteration, the reduced susceptibility can cause cross-resistance or just resistance to a subset of derivatives [44].

Although the role of ERG11 gene point mutations in azole resistance is a well-recognized phenomenon in Candida spp. [38], only recently a few studies have characterized the polymorphisms of the ERG11 gene in azole-resistant isolates of the C. hameulonii complex [2,13]. In the study of Gade et al. [2], an increasing azole resistance in isolates of C. haemulonii and C. duobushaemulonii was evidenced in Colombia, Panama, and Venezuela, associated with substitutions in the ERG11 gene, suggesting the existence of an evolutionary pressure for the development of azoles resistance in Latin America. In the present study, eight of the 12 ERG11 gene mutations have been reported to be associated with reduced azole susceptibility in C. albicans—namely, F105L, S110A, D116A, K119S, D153E, R267T, A432S, and F487Y. However, Erg11p substitutions F126L, Y132F, and K143R, which were implicated in reduced susceptibilities to azoles upon heterologous expression in S. cerevisiae [45,46], were not identified in our isolates. Corroborating our data, a recent study by Rodrigues et al. [13] again found that Brazilian resistant isolates of C. haemulonii var. vulnera also lacked these common mutations. Thus, the ERG11 gene mutations by themselves cannot explain the differences between the distinct multi-azole profile in our isolates. ERG11, ERG3, and ERG5 combinatorial alterations in Candida have shown to circumvent this pathway and led to the development of cross-resistance to azoles and AMB [47–50]. Using multi-omics approaches, Zamith-Miranda et al. [51] showed that a resistant isolate of C. auris displays a significant higher abundance of Erg2p and a lower abundance of Erg3p. As a matter of fact, we have demonstrated by GC-MS that the C. haemulonii species sterol profiles were comparable to those of different Candida species with ERG2, ERG3, ERG6m and ERG11 gene mutations, presenting the same cross-resistance profile [21]. Along with our results, recent literature reports have suggested that azole resistance in C. haemulonii clade can be related to multiple-steps modifications in the ergosterol biosynthesis pathway [45,51].

Azole resistance has also been attributed to fungal cells that have lost mitochondrial function resulting in respiratory deficiency [52–55]. Precisely, in S. cerevisiae, C. glabrata, and A. fumigatus, mitochondrial dysfunction has displayed multiple effects in fungal cells, and this can enlighten us on the enhanced efflux pumps’ activities [53,56,57]. These fungal cells usually exhibit an altered sterol profile with an unequal amount of ergosterol; still, no changes in the sequence of ERG11 gene or its expression have been detected [57,58]. Our recently published work demonstrated primary evidence that impairment of the mitochondrial function in C. haemulonii species complex intensifies the tolerance to stress and could be related with a rearrangement in the cellular ergosterol content [21]. In this context, growing evidence from recent elegant reports has revealed that there are more complicated and unknown drug resistance mechanisms apart from the mutational modification of the azole target ERG11p in fungal pathogens [59–62].

5. Conclusions

Indeed, the widespread use of azoles has been considered to be an important risk factor for FLC resistance development primarily in non-albicans Candida species. In this context, an assessment of all possible resistance mechanisms is important for a proper patient treatment outcome. Our data suggest an emergence of azole-resistant clinical isolates belonging to the C. haemulonii species complex
recovered from Brazilian patients. This study provides significant evidence that efflux pump activity is implicated in high-level FLC resistance and pan-azole resistance in the *C. haemulonii* complex. Once there is an increasing azole resistance among *C. haemulonii* complex isolates, further surveillance is warranted.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2309-608X/6/4/215/s1, Table S1: Antifungal susceptibility profiles of the clinical isolates belonging to the *Candida haemulonii* species complex to different azole agents, Table S2: Antifungal susceptibility profiles of the non-albicans *Candida* species to different azole agents, Table S3: Homology search results comparing *Candida albicans* (SC5314) and *Candida haemulonii* (B11899) genes via BLAST.

**Author Contributions:** All the authors conceived and designed the experiments. L.N.S., L.d.S.R., S.S.C.O., L.B.M. and E.D.S. performed the experiments. All the authors analyzed the data. L.K., M.H.V., M.H.B. and A.L.S.d.S. contributed reagents/materials/analysis tools and funding acquisition. All the authors wrote and revised the paper. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by grants from Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Financial code 001).

**Acknowledgments:** The authors would like to thank Denise da Rocha de Souza, who is supported by a FAPERJ fellowship, for technical assistance and Diogo de Azevedo Jurelevicius (Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil) for the help with the sequence analysis.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Cendejas-Bueno, E.; Kolecka, A.; Alastruey-Izquierdo, A.; Theelen, B.; Groenewald, M.; Kostrzewa, M.; Cuenca-Estrella, M.; Gomez-Lopez, A.; Boekhout, T. Reclassification of the *Candida haemulonii* complex as *Candida haemulonii* (C. haemulonii group I), *C. duobushaemulonii* sp. nov. (C. haemulonii group II), and *C. haemulonii* var. *vulnera* var. nov.: Three multiresistant human pathogenic yeasts. *J. Clin. Microbiol.* 2012, 50, 3641–3651. [CrossRef]

2. Gade, L.; Muñoz, J.F.; Sheth, M.; Wagner, D.; Berkow, E.L.; Forsberg, K.; Jackson, B.R.; Ramos-Castro, R.; Escandón, P.; Dolande, M.; et al. Understanding the emergence of multidrug-resistant *Candida*: Using whole-genome sequencing to describe the population structure of *Candida haemulonii* species complex. *Front. Genet.* 2020, 11, 554. [CrossRef] [PubMed]

3. Coles, M.; Cox, K.; Chao, A. *Candida haemulonii*: An emerging opportunistic pathogen in the United States? *IDCases* 2020, 21, e00990. [CrossRef] [PubMed]

4. Hou, X.; Xiao, M.; Chen, S.C.; Wang, H.; Cheng, J.W.; Chen, X.X.; Xu, Z.P.; Fan, X.; Kong, F.; Xu, Y.C. Identification and antifungal susceptibility profiles of *Candida haemulonii* species complex clinical isolates from a multicenter study in China. *J. Clin. Microbiol.* 2016, 54, 2676–2680. [CrossRef] [PubMed]

5. Kim, M.N.; Shin, J.H.; Sung, H.; Lee, K.; Kim, E.C.; Ryoo, N.; Lee, J.S.; Jung, S.I.; Park, K.H.; Kee, S.J.; et al. *Candida haemulonii* and closely related species at 5 university hospitals in Korea: Identification, antifungal susceptibility, and clinical features. *Clin. Infect. Dis.* 2009, 48, e57–e61. [CrossRef] [PubMed]

6. Ben-Ami, R.; Berman, J.; Novikov, A.; Bash, E.; Shachor-Meyouhas, Y.; Zakin, S.; Maor, Y.; Tarabia, J.; Schechner, V.; Adler, A.; et al. Multidrug-resistant *Candida haemulonii* and *C. auris*, Tel Aviv, Israel. *Emerg. Infect. Dis.* 2017, 23, 195–203. [CrossRef] [PubMed]

7. Frías-De-León, M.G.; Martínez-Herrera, E.; Acosta-Altamirano, G.; Arenas, R.; Rodriguez-Cerdeira, C. Superficial candidosis by *Candida duobushaemulonii*: An emerging microorganism. *Infec. Genet. Evol.* 2019, 75, 1–5. [CrossRef] [PubMed]

8. Fang, S.Y.; Wei, K.C.; Chen, W.C.; Lee, S.J.; Yang, K.C.; Wu, C.S.; Sun, P.L. Primary deep cutaneous candidiasis caused by *Candida duobushaemulonii* in a 68-year-old man: The first case report and literature review. *Mycoses* 2016. [CrossRef]

9. Kumar, A.; Prakash, A.; Singh, A.; Kumar, H.; Hagen, F.; Meis, J.F.; Chowdhary, A. *Candida haemulonii* species complex: An emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. *Emerg. Microbes Infect.* 2016, 5, 1–3. [CrossRef]
10. Ramos, L.S.; Figueiredo-Cardalho, M.H.G.; Barbedo, L.S.; Ziccardi, M.; Chaves, A.L.S.; Zancope-Oliveira, R.M.; Pinto, M.R.; Sgarbi, D.B.G.; Dornelas-Ribeiro, M.; Branquinha, M.H.; et al. *Candida haemulonii* complex: Species identification and antifungal susceptibility profiles of clinical isolates from Brazil. *J. Antimicrob. Chemother.* 2015, 70, 111–115. [CrossRef]  
11. De Almeida, J.N., Jr.; Assy, J.G.; Levin, A.S.; Del Negro, G.M.; Giudice, M.C.; Trinomi, M.P.; Thomaz, D.Y.; Motta, A.L.; Abdala, E.; Pierroti, L.C.; et al. *Candida haemulonii* complex species, Brazil, January 2010-March 2015. *Emerg. Infect. Dis.* 2016, 22, 561–563. [CrossRef] [PubMed]  
12. Muro, M.D.; Motta, F.d.A.; Burger, M.; Melo, A.S.d.A.; Dalla-Costa, L.M. Echinocandin resistance in two *Candida haemulonii* isolates from pediatric patients. *J. Clin. Microbiol.* 2012, 50, 3783–3785. [CrossRef] [PubMed]  
13. Rodrigues, L.S.; Gazara, R.K.; Passarelli-Araujo, H.; Valengo, A.E.; Pontes, P.V.M.; Nunes-da-Fonseca, R.; de Souza, R.F.; Venancio, T.M.; Dalla-Costa, L.M. First genome sequences of two multidrug-resistant *Candida haemulonii* var. *vulnera* isolates from pediatric patients with candidemia. *Front. Microbiol.* 2020, 11, 1535. [CrossRef]  
14. Pfaffer, M.A.; Diekema, D.J.; Gibbs, D.L.; Newell, V.A.; Ellis, D.; Tullio, V.; Rodlo, A.; Fu, W.; Ling, T.A. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of *Candida* species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. *J. Clin. Microbiol.* 2010, 48, 1366–1377. [CrossRef] [PubMed]  
15. Oberoi, J.K.; Wattal, C.; Goel, N.; Raveendran, R.; Datta, S.; Prasad, K. Non-*albicans* *Candida* species in blood stream infections in a tertiary care hospital at New Delhi, India. *Indian J. Med. Res.* 2012, 136, 997–1003. [CrossRef] [PubMed]  
16. Xiao, M.; Chen, S.C.; Kong, F.; Xu, X.L.; Yan, L.; Kong, H.S.; Fan, X.; Hou, X.; Cheng, J.W.; Zhou, M.L.; et al. Distribution and antifungal susceptibility of *Candida* species causing candidemia in China: An update from the CHIF-NET study. *J. Infect. Dis.* 2020, 221, 139–147. [CrossRef] [PubMed]  
17. Lima, S.L.; Francisco, E.C.; de Almeida Júnior, J.N.; Santos, D.; Carlesse, F.; Queiroz-Telles, F.; Melo, A.S.A.; Colombo, A.L. Increasing prevalence of multidrug-resistant *Candida haemulonii* species complex among all yeast cultures collected by a reference laboratory over the past 11 years. *J. Fungi* 2020, 6, 110. [CrossRef] [PubMed]  
18. Silva, L.N.; Mello, T.P.; Ramos, L.S.; Branquinha, M.H.; Santos, A.L.S. New and promising chemotherapeutics for emerging infections involving drug-resistant non-*albicans* *Candida* species. *Curr. Top. Med. Chem.* 2019, 19, 1–27. [CrossRef]  
19. Chaabane, F.; Graf, A.; Jequier, L.; Coste, A.T. Review on antifungal resistance mechanisms in the emerging pathogen *Candida auris*. *Front. Microbiol.* 2019, 10, 1–8. [CrossRef]  
20. Colombo, A.L.; Júnior, J.N.A.; Guinea, J. Emerging multidrug-resistant *Candida* species. *Curr. Opin. Infect. Dis.* 2017, 30, 528–538. [CrossRef]  
21. Silva, L.N.; Oliveira, S.S.C.; Magalhães, L.B.; Andrade Neto, V.V.; Torres-Santos, E.C.; Carvalho, M.D.C.; Pereira, M.D.; Branquinha, M.H.; Santos, A.L.S. Unmasking the amphotericin B resistance mechanisms in *Candida haemulonii* species complex. *ACS Infect. Dis.* 2020, 6, 1273–1282. [CrossRef] [PubMed]  
22. Perlin, D.S.; Rautemaa-Richardson, R.; Alastruey-Izquierdo, A. The global problem of antifungal resistance: Prevalence, mechanisms, and management. *Lancet Infect. Dis.* 2017, 17, 383–392. [CrossRef]  
23. Muñoz, J.F.; Gade, L.; Chow, N.A.; Loparev, V.N.; Jueng, P.; Berkow, E.L.; Farrer, R.A.; Litvintseva, A.P.; Cuomo, C.A. Genomic insights into multidrug-resistance, mating and virulence in *Candida auris* and related emerging species. *Nat. Commun.* 2018, 9, 1–13.  
24. Zhang, H.; Niu, Y.; Tan, J.; Liu, W.; Sun, M.-A.; Yang, E.; Wang, Q.; Li, R.; Wang, Y.; Liu, W. Global screening of genomic and transcriptomic factors associated with phenotype differences between multidrug-resistant and -susceptible *Candida haemulonii* strains. *mSystems* 2019, 4, 1–17. [CrossRef]  
25. Rybak, J.M.; Doorley, L.A.; Nishimoto, A.T.; Barker, K.S.; Palmer, G.E.; Rogers, P.D. Abrogation of triazole resistance upon deletion of *CDR1* in a clinical isolate of *Candida auris*. *Antimicrob. Agents Chemother.* 2019, 63. [CrossRef]  
26. CLSI (Clinical and Laboratory Standards Institute). M27-A3: *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts*, 3rd ed.; CLSI: Wayne, PA, USA, 2008.  
27. Maesaki, S.; Marichal, P.; Vanden Bossche, H.; Sanglard, D.; Kohno, S. Rhodamine 6G efflux for the detection of *CDR1*-overexpressing azole-resistant *Candida albicans* strains. *J. Antimicrob. Chemother.* 1999, 44, 27–31. [CrossRef]
28. Kean, R.; Delaney, C.; Sherry, L.; Borman, A.; Johnson, E.M.; Richardson, M.D.; Rautemaa-Richardson, R.; Williams, C.; Ramage, G. Transcriptome assembly and profiling of Candida auris reveals novel insights into biofilm-mediated resistance. mSphere 2018, 3, 1–14. [CrossRef]

29. Squizani, E.D.; Oliveira, N.K.; Reuwsaat, J.C.V.; Marques, B.M.; Lopes, W.; Gerber, A.L.; de Vasconcelos, A.T.R.; Lev, S.; Djordjevic, J.T.; Schrank, A.; et al. Cryptococcal dissemination to the central nervous system requires the vacuolar calcium transporter Pmc1. Cell. Microbiol. 2018, 20, 1–13. [CrossRef]

30. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta Ct}$ method. Methods 2001, 25, 402–408. [CrossRef]

31. Chowdhary, A.; Prakash, A.; Sharma, C.; Kordalewska, M.; Kumar, A.; Sarma, S.; Tarai, B.; Singh, A.; Upadhyay, G.; Upadhyay, S.; et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J. Antimicrob. Chemother. 2018, 73, 891–899. [CrossRef]

32. Arnaud, M.B.; Costanzo, M.C.; Skrzypek, M.S.; Shah, P.; Binkley, G.; Lane, C.; Miyasato, S.R.; Sherlock, G. Sequence resources at the Candida Genome Database. Nucleic Acids Res. 2007, 35, 452–456. [CrossRef] [PubMed]

33. Morio, F.; Loge, C.; Besse, B.; Hennequin, C.; Le Pape, P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: New substitutions and a review of the literature. Diagn. Microbiol. Infect. Dis. 2010, 66, 373–384. [CrossRef] [PubMed]

34. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C.; Tamura, K. MEGA X: Molecular evolutionary genetics analysis across computing platforms. Mol. Biol. Evol. 2018, 35, 1547–1549. [CrossRef] [PubMed]

35. Flowers, S.A.; Colón, B.; Whaley, S.G.; Schuler, M.A.; Rogers, P.D. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob. Agents Chemother. 2015, 59, 450–460. [CrossRef] [PubMed]

36. Lockhart, S.R.; Etienne, K.A.; Vallabhaneni, S.; Farooqi, J.; Chowdhary, A.; Govender, N.P.; Colombo, A.L.; Calvo, B.; Cuomo, C.A.; Desjardins, C.A.; et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. 2017, 64, 134–140. [CrossRef]

37. Silva, L.N.; Campos-Silva, R.; Ramos, L.S.; Trentin, D.S.; Macedo, A.J.; Branquinha, M.H.; Santos, A.L.S. Virulence of Candida haemulonii complex in Galleria mellonella and efficacy of classical antifungal drugs: A comparative study with other clinically relevant non-albicans Candida species. FEMS Yeast Res. 2018, 18, foy082. [CrossRef]

38. Fakhim, H.; Vaezi, A.; Dannaoui, E.; Chowdhary, A.; Nasiry, D.; Faeli, L.; Meis, J.F.; Badali, H. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model. Mycoses 2018, 61, 377–382. [CrossRef]

39. Arendrup, M.C.; Patterson, T.F. Multidrug-resistant Candida: Epidemiology, molecular mechanisms, and treatment. J. Infect. Dis. 2017, 216, S445–S451. [CrossRef]

40. Sun, S.; Li, Y.; Guo, Q.; Shi, C.; Yu, J.; Ma, L. In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob. Agents Chemother. 2008, 52, 409–417. [CrossRef]

41. Li, H.; Chen, Z.; Zhang, C.; Gao, Y.; Zhang, X.; Sun, S. Resistance reversal induced by a combination of fluconazole and tacrolimus (FK506) in Candida glabrata. J. Med. Microbiol. 2015, 64, 44–52. [CrossRef]

42. Pandey, N.; Tripathi, M.; Gupta, M.K.; Tilak, R. Overexpression of efflux pump transporter genes and mutations in ERG11 pave the way to fluconazole resistance in Candida tropicalis: A study from North India region. J. Glob. Antimicrob. Resist. 2020, 22, 374–378. [CrossRef] [PubMed]

43. Maertens, J.A. History of the development of azole derivatives. Clin. Microbiol. Infect. 2004, 10, 1–10. [CrossRef] [PubMed]

44. Zavrel, M.; Esquivel, B.D.; White, T.C. The ins and outs of azole antifungal drug resistance: Molecular mechanisms of transport. In Handbook of Antimicrobial Resistance; Berghuis, A., Matlashewski, G., Wainberg, M.A., Sheppard, D., Eds.; Springer: New York, NY, USA, 2017; pp. 423–452. [CrossRef]

45. Healey, K.R.; Kordalewska, M.; Jiménez Ortigosa, C.; Singh, A.; Berrio, I.; Chowdhary, A.; Perlin, D.S. Limited ERG11 mutations identified in isolates of Candida auris directly contribute to reduced azole susceptibility. Antimicrob. Agents Chemother. 2018, 62, 1–14. [CrossRef] [PubMed]

46. Xiang, M.-J.; Liu, J.-Y.; Ni, P.-H.; Wang, S.; Shi, C.; Wei, B.; Ni, Y.-X.; Ge, H.-L. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res. 2013, 13, 386–393. [CrossRef]
47. Sanglard, D.; Ischer, F.; Parkinson, T.; Falconer, D.; Bille, J. *Candida albicans* mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. *Antimicrob. Agents Chemother.* 2003, 47, 2404–2412. [CrossRef]

48. Hull, C.M.; Parker, J.E.; Bader, O.; Weig, M.; Gross, U.; Warrilow, A.G.S.; Kelly, D.E.; Kelly, S.L. Facultative sterol uptake in an ergosterol-deficient clinical isolate of *Candida glabrata* harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. *Antimicrob. Agents Chemother.* 2012, 56, 4223–4232. [CrossRef]

49. Forastiero, A.; Mesa-Arango, A.C.; Alastruey-Izquierdo, A.; Alcazar-Fuoli, L.; Bernal-Martinez, L.; Pelaez, T.; Lopez, J.F.; Grimalt, J.O.; Gomez-Lopez, A.; Cuesta, I.; et al. *Candida tropicalis* antifungal cross-resistance is related to different azole target (Erg11p) modifications. *Antimicrob. Agents Chemother.* 2013, 57, 4769–4781. [CrossRef]

50. Martel, C.M.; Parker, J.E.; Bader, O.; Weig, M.; Gross, U.; Warrilow, A.G.S.; Kelly, D.E.; Kelly, S.L. A clinical isolate of *Candida albicans* with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. *Antimicrob. Agents Chemother.* 2010, 54, 3578–3583. [CrossRef]

51. Zamith-Miranda, D.; Heyman, H.M.; Cleare, L.G.; Couvillion, S.P.; Clair, G.C.; Bredeweg, E.L.; Gacser, A.; Nimrichter, L.; Nakayasu, E.S.; Nosanchuk, J.D. Multi-omics signature of *Candida auris*, an emerging and multidrug-resistant pathogen. *mSystems* 2019, 4, 1–14. [CrossRef]

52. Peng, Y.; Dong, D.; Jiang, C.; Yu, B.; Wang, X.; Ji, Y. Relationship between respiration deficiency and azole resistance in clinical *Candida glabrata*. *FEMS Yeast Res.* 2012, 12, 719–727. [CrossRef]

53. Ferrari, S.; Sanguinetti, M.; De Bernardis, F.; Torelli, R.; Posteraro, B.; Vandeputte, P.; Sanglard, D. Loss of mitochondrial functions associated withazole resistance in *Candida glabrata* results in enhanced virulence in mice. *Antimicrob. Agents Chemother.* 2011, 55, 1852–1860. [CrossRef] [PubMed]

54. Thomas, E.; Roman, E.; Claypool, S.; Manzoor, N.; Pla, J.; Panwar, S.L. Mitochondria influence pump activity, Hog1-mediated oxidative stress pathway, iron homeostasis, and ergosterol levels in *Candida albicans*. *Antimicrob. Agents Chemother.* 2013, 57, 5580–5599. [CrossRef] [PubMed]

55. Brun, S.; Aubry, C.; Lima, O.; Filmon, R.; Bergès, T.; Chabasse, D.; Bouchara, J.P. Relationships between respiration and susceptibility to azole antifungals in *Candida glabrata*. *Antimicrob. Agents Chemother.* 2003, 47, 847–853. [CrossRef] [PubMed]

56. Hallstrom, T.C.; Moye-Rowley, W.S. Multiple signals from dysfunctional mitochondria activate the pleiotropic drug resistance pathway in *Saccharomyces cerevisiae*. *J. Biol. Chem.* 2000, 275, 37347–37356. [CrossRef]

57. Sharma, C.; Nelson-Sathi, S.; Singh, A.; Radhakrishna Pillai, M.; Chowdhary, A. Genomic perspective of triazole resistance in clinical and environmental *Aspergillus fumigatus* isolates without cyp51A mutations. *Fungal Genet. Biol.* 2019, 132, 103265. [CrossRef]

58. Brun, S.; Bergès, T.; Poupard, P.; Vauzelle-Moreau, C.; Renier, G.; Chabasse, D.; Bouchara, J.P. Mechanisms of azole resistance in petite mutants of *Candida glabrata*. *Antimicrob. Agents Chemother.* 2004, 48, 1788–1796. [CrossRef]

59. Hagiwara, D.; Arai, T.; Takahashi, H.; Kusuya, Y.; Watanabe, A.; Kamei, K. Non-cyp51A azole-resistant Aspergillus fumigatus isolates with mutation in HMG-CoA reductase. *Emerg. Infect. Dis.* 2018, 24, 1889–1897. [CrossRef]

60. Li, Y.; Zhang, Y.; Zhang, C.; Wang, H.; Wei, X.; Chen, P.; Lu, L. Mitochondrial dysfunctions trigger the calcium signaling-dependent fungal multidrug resistance. *Proc. Natl. Acad. Sci. USA* 2020, 117, 1711–1721. [CrossRef]

61. Gao, J.; Wang, H.; Li, Z.; Wong, A.H.-H.; Wang, Y.-Z.; Guo, Y.; Lin, X.; Zeng, G.; Liu, H.; Wang, Y.; et al. *Candida albicans* gains azole resistance by altering sphingolipid composition. *Nat. Commun.* 2018, 9, 4495. [CrossRef]

62. Mayr, E.M.; Ramírez-Zavaleta, B.; Krüger, I.; Morschhäuser, J. A zinc cluster transcription factor contributes to the intrinsic fluconazole resistance of *Candida auris*. *mSphere* 2020, 5, e00279-20. [CrossRef]